Advertisement

Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population

      Abstract

      Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, has been shown to be involved in the pathogenesis of atherosclerosis. The present study was initiated to investigate the role of ADMA as a risk marker of acute cerebrovascular disease (CVD).
      We examined 363 CVD patients and 48 controls. The ADMA concentration (mean ± S.D., μmol/L) in controls was 0.50 ± 0.06. Compared to controls, increased concentrations of ADMA were observed in cardio-embolic infarction (0.55 ± 0.08; p < 0.001; n = 71), and TIA (0.54 ± 0.05; p < 0.001; n = 31), but not in non-cardio-embolic infarction (0.51 ± 0.07; p = 0.56; n = 239) and haemorrhagic stroke (0.51 ± 0.11; p = 0.77; n = 22). In multivariate logistic regression models, CVD increased across quartiles of ADMA in all subgroups, but this association was only significant in the TIA group (odds ratio for highest versus lowest quartile 13.1; 95% CI: 2.9–58.6; p trend 0.001) A decreased arginine/ADMA ratio was significantly associated with CVD in the entire study population (p < 0.01). Our results indicate that ADMA is a weak independent marker for acute stroke and a strong marker for TIA and that relative arginine deficiency, measured as the l-arginine/ADMA ratio, is present in acute CVD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Elkind M.S.
        • Sacco R.L.
        Stroke risk factors and stroke prevention.
        Sem Neurol. 1998; 18: 429-440
        • Higashi Y.
        • Oshima T.
        • Sasaki N.
        • et al.
        Relationship between insulin resistance and endothelium dependent vascular relaxation in patients with essential hypertension.
        Hypertension. 1997; 29: 280-285
        • Miyazaki H.
        • Matsuoka H.
        • Cooke J.P.
        Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis.
        Circulation. 1999; 99: 1141-1146
        • Cooke J.P.
        • Dzau V.J.
        Nitric oxide synthase: role in the genesis of vascular disease.
        Annu Rev Med. 1997; 48: 489-509
        • McAllister R.J.
        • Fickling S.A.
        • Whitley G.S.J.
        • Vallence
        Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis.
        Br J Pharmacol. 1992; 112: 43-48
        • Vallance P.
        • Leone A.
        • Calver A.
        • Collier J.
        • Moncada S.
        Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis.
        J Cardiovasc Pharmacol. 1992; 20: S60-S62
        • Valkonen V.P.
        • Päivä H.
        • Salonen J.T.
        • et al.
        Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.
        Lancet. 2001; 358: 2127-2128
        • Lu T.M.
        • Ding Y.A.
        • Lin S.J.
        • Lee W.S.
        • Tai H.C.
        Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.
        Eur Heart J. 2003; 24: 1912-1919
        • Yoo J.-H.
        • Lee S.-C.
        Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke.
        Atherosclerosis. 2001; 158: 425-430
        • Aho K.
        • Harmsen P.
        • Hatano S.
        • Marquardsen J.
        • Smirnov V.E.
        • Strasser T.
        Cerebrovascular disease in the community: results of a WHO collaboration study.
        Bull World Health Organ. 1980; 58: 113-130
      1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.

        • Bluth E.I.
        • Wetzner S.M.
        • Stavros A.T.
        • Aufrichtig D.
        • Marish K.W.
        • Baker J.D.
        Carotid duplex sonography: a multicenter recommendation for standardized imaging and Doppler criteria.
        RadioGraphics. 1988; 8 (Fig. 22): 487-506
        • Jeppsson J.O.
        • Jerntorp P.
        • Sundkvist G.
        • Englund H.
        • Nylund V.
        Measurement of hemoglobin A1c by a new liquid-chromatography assay; methodology, clinical utility, and relation to tolerance evaluated.
        Clin Chem. 1986; 32: 1867-1872
        • Teerlink T.
        • Nijveldt R.J.
        • de Jong S.
        • van Leeuwen PA.M.
        Determination of arginine, asymmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography.
        Anal Biochem. 2002; 303: 131-137
        • Böger R.H.
        The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
        Cardiovasc Res. 2003; 59: 824-833
        • van der Wal A.C.
        • Becker A.E.
        • van der Loos C.M.
        • Das P.K.
        Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.
        Circulation. 1994; 89: 36-44
        • Lundman P.
        • Eriksson M.J.
        • Stűhlinger M.
        • Cooke J.P.
        • Hamsten A.
        • Tornvall P.
        Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine.
        J Am Coll Cardiol. 2001; 38: 111-116
        • Stűhlinger M.C.
        • Oka R.K.
        • Graf E.E.
        • et al.
        Endothelial dysfunction induced hyperhomocysteinemia: role of asymmetric dimethylarginine.
        Circulation. 2003; 108: 933-938
        • Böger R.H.
        • Bode-Böger S.M.
        • Szuba A.
        • et al.
        Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
        Circulation. 1998; 98: 1842-1847
        • Lin K.Y.
        • Ito A.
        • Asagami T.
        • et al.
        Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
        Circulation. 2002; 106: 987-992
        • Nijveldt R.J.
        • Teerlink T.
        • Siroen M.P.C.
        • van Lambalgen A.A.
        • Rauwerda J.A.
        • van Leeuwen P.A.
        The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA).
        Clin Nutr. 2003; 22: 17-20
        • Abbasi F.
        • Asagmi T.
        • Coke J.P.
        • et al.
        Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.
        Am J Cardiol. 2001; 88: 1201-1203
        • Surdacki A.
        • Nowicki M.
        • Sandmann J.
        Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension.
        J Cardiovasc Pharmacol. 1999; 33: 652-658
        • Böger R.H.
        • Bode-Böger S.M.
        • Thiele W.
        • Junker W.
        • Alexander K.
        • Frölich J.C.
        Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.
        Circulation. 1997; 95: 2068-2074
        • Purroy F.
        • Montaner J.
        • Rovira A.
        • Delgado P.
        • Quintana M.
        • Alvarez-Sabin J.
        Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions.
        Stroke. 2004; 35: 2313-2319
        • Chan N.N.
        • Chan J.C.
        Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?.
        Diabetologia. 2002; 45: 1609-1616
        • Jeserich M.
        • Műnzel T.
        • Just H.
        • Drexler H.
        Reduced plasma l-arginine in hyper-cholesterolemia.
        Lancet. 1992; 339: 561
        • Lu T.M.
        • Ding Y.A.
        • Leu H.B.
        • Yin W.H.
        • Sheu W.H.
        • Chu K.M.
        Effect of rozuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
        Am J Cardiol. 2004; 94: 157-161